Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Measuring Vaccine Responses in the Multiplex Era.

Ayling K, Vedhara K, Fairclough L.

Methods Mol Biol. 2018;1781:327-340. doi: 10.1007/978-1-4939-7828-1_17.

PMID:
29705855
2.

Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics.

Huckle AW, Fairclough LC, Todd I.

Respir Care. 2018 May;63(5):609-619. doi: 10.4187/respcare.05943. Epub 2018 Feb 20. Review.

PMID:
29463692
3.

Characterization of Behavioral, Signaling and Cytokine Alterations in a Rat Neurodevelopmental Model for Schizophrenia, and Their Reversal by the 5-HT6 Receptor Antagonist SB-399885.

Shortall SE, Negm OH, Fowler M, Fairclough LC, Tighe PJ, Wigmore PM, King MV.

Mol Neurobiol. 2018 Feb 8. doi: 10.1007/s12035-018-0940-0. [Epub ahead of print]

PMID:
29423817
4.

IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review.

Saniklidou AH, Tighe PJ, Fairclough LC, Todd I.

Arch Dermatol Res. 2018 Jan;310(1):11-28. doi: 10.1007/s00403-017-1789-1. Epub 2017 Oct 25. Review.

5.

Autoantibodies of IgM and IgG classes show differences in recognition of multiple autoantigens in chronic obstructive pulmonary disease.

Shindi R, Almehairi A, Negm OH, Kalsheker N, Gale NS, Shale DJ, Harrison TW, Bolton CE, John M, Todd I, Tighe PJ, Fairclough LC.

Clin Immunol. 2017 Oct;183:344-353. doi: 10.1016/j.clim.2017.09.020. Epub 2017 Sep 23.

PMID:
28951328
6.

Positive mood on the day of influenza vaccination predicts vaccine effectiveness: A prospective observational cohort study.

Ayling K, Fairclough L, Tighe P, Todd I, Halliday V, Garibaldi J, Royal S, Hamed A, Buchanan H, Vedhara K.

Brain Behav Immun. 2018 Jan;67:314-323. doi: 10.1016/j.bbi.2017.09.008. Epub 2017 Sep 18.

7.

A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing.

Todd I, Negm OH, Reps J, Radford P, Figueredo G, McDermott EM, Drewe E, Powell RJ, Bainbridge S, Hamed M, Crouch S, Garibaldi J, St-Gallay S, Fairclough LC, Tighe PJ.

Pharmacol Res. 2017 Nov;125(Pt B):188-200. doi: 10.1016/j.phrs.2017.08.012. Epub 2017 Aug 30.

PMID:
28860008
8.

Peripheral killer cells do not differentiate between asthma patients with or without fixed airway obstruction.

Tubby C, Negm OH, Harrison T, Tighe PJ, Todd I, Fairclough LC.

J Asthma. 2017 Jun;54(5):456-466. doi: 10.1080/02770903.2016.1236941. Epub 2016 Oct 13.

PMID:
27736259
9.

The application of protein microarray assays in psychoneuroimmunology.

Ayling K, Bowden T, Tighe P, Todd I, Dilnot EM, Negm OH, Fairclough L, Vedhara K.

Brain Behav Immun. 2017 Jan;59:62-66. doi: 10.1016/j.bbi.2016.09.013. Epub 2016 Sep 14.

PMID:
27640078
10.

Multiple Circulating Cytokines Are Coelevated in Chronic Obstructive Pulmonary Disease.

Selvarajah S, Todd I, Tighe PJ, John M, Bolton CE, Harrison T, Fairclough LC.

Mediators Inflamm. 2016;2016:3604842. doi: 10.1155/2016/3604842. Epub 2016 Jul 25.

11.

Modifying Hofstee standard setting for assessments that vary in difficulty, and to determine boundaries for different levels of achievement.

Burr SA, Whittle J, Fairclough LC, Coombes L, Todd I.

BMC Med Educ. 2016 Jan 28;16:34. doi: 10.1186/s12909-016-0555-y.

12.

Tumour necrosis factor receptor I blockade shows that TNF-dependent and TNF-independent mechanisms synergise in TNF receptor associated periodic syndrome.

Fairclough LC, Stoop AA, Negm OH, Radford PM, Tighe PJ, Todd I.

Eur J Immunol. 2015 Oct;45(10):2937-44. doi: 10.1002/eji.201545769. Epub 2015 Aug 17.

13.

Ex vivo and in vitro production of pro-inflammatory cytokines in Blau syndrome.

Galozzi P, Negm O, Greco E, Alkhattabi N, Gava A, Sfriso P, Fairclough L, Todd I, Tighe P, Punzi L.

Reumatismo. 2015 Mar 31;66(4):277-84. doi: 10.4081/reumatismo.2014.772.

14.

ELISA in the multiplex era: potentials and pitfalls.

Tighe PJ, Ryder RR, Todd I, Fairclough LC.

Proteomics Clin Appl. 2015 Apr;9(3-4):406-22. doi: 10.1002/prca.201400130. Epub 2015 Mar 25. Review.

PMID:
25644123
15.

Natural and disease-specific autoantibodies in chronic obstructive pulmonary disease.

Daffa NI, Tighe PJ, Corne JM, Fairclough LC, Todd I.

Clin Exp Immunol. 2015 Apr;180(1):155-63. doi: 10.1111/cei.12565.

16.

Development and validation of protein microarray technology for simultaneous inflammatory mediator detection in human sera.

Selvarajah S, Negm OH, Hamed MR, Tubby C, Todd I, Tighe PJ, Harrison T, Fairclough LC.

Mediators Inflamm. 2014;2014:820304. doi: 10.1155/2014/820304. Epub 2014 Oct 14.

17.

A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS).

Negm OH, Mannsperger HA, McDermott EM, Drewe E, Powell RJ, Todd I, Fairclough LC, Tighe PJ.

Eur J Immunol. 2014 Jul;44(7):2096-110. doi: 10.1002/eji.201344328. Epub 2014 Jun 10.

18.

Modifying the Hofstee method may overcome problems.

Todd I, Burr S, Whittle J, Fairclough L.

Med Teach. 2014 Apr;36(4):358-9. doi: 10.3109/0142159X.2014.887842. Epub 2014 Feb 18. No abstract available.

PMID:
24548113
19.

Canadian Cancer Risk Management Model: evaluation of cancer control.

Evans WK, Wolfson MC, Flanagan WM, Shin J, Goffin J, Miller AB, Asakawa K, Earle C, Mittmann N, Fairclough L, Oderkirk J, Fin├Ęs P, Gribble S, Hoch J, Hicks C, Omariba DW, Ng E.

Int J Technol Assess Health Care. 2013 Apr;29(2):131-9. doi: 10.1017/S0266462313000044. Epub 2013 Mar 20.

PMID:
23514623
20.

Differential activation of killer cells in the circulation and the lung: a study of current smoking status and chronic obstructive pulmonary disease (COPD).

Wang J, Urbanowicz RA, Tighe PJ, Todd I, Corne JM, Fairclough LC.

PLoS One. 2013;8(3):e58556. doi: 10.1371/journal.pone.0058556. Epub 2013 Mar 11.

21.

Utility, reliability and reproducibility of immunoassay multiplex kits.

Tighe P, Negm O, Todd I, Fairclough L.

Methods. 2013 May 15;61(1):23-9. doi: 10.1016/j.ymeth.2013.01.003. Epub 2013 Jan 16.

PMID:
23333412
22.

Accelerating knowledge to action: the pan-Canadian cancer control strategy.

Fairclough L, Hill J, Bryant H, Kitchen-Clarke L.

Curr Oncol. 2012 Apr;19(2):70-7. doi: 10.3747/co.19.1019.

23.

Optimizing community and stakeholder engagement in a merger of community health centres.

Cohen A, Fairclough L, Jass J.

Healthc Manage Forum. 2011 Winter;24(4):192-5.

PMID:
22256516
24.

Genome-wide analysis of gene expression during Xenopus tropicalis tadpole tail regeneration.

Love NR, Chen Y, Bonev B, Gilchrist MJ, Fairclough L, Lea R, Mohun TJ, Paredes R, Zeef LA, Amaya E.

BMC Dev Biol. 2011 Nov 15;11:70. doi: 10.1186/1471-213X-11-70.

25.

Immunological basis of reversible and fixed airways disease.

Tubby C, Harrison T, Todd I, Fairclough L.

Clin Sci (Lond). 2011 Oct;121(7):285-96. doi: 10.1042/CS20110062. Review.

PMID:
21651498
26.

The secreted integrin ligand nephronectin is necessary for forelimb formation in Xenopus tropicalis.

Abu-Daya A, Nishimoto S, Fairclough L, Mohun TJ, Logan MP, Zimmerman LB.

Dev Biol. 2011 Jan 15;349(2):204-12. doi: 10.1016/j.ydbio.2010.10.015. Epub 2010 Oct 23.

27.

Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients.

Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC.

Respir Res. 2010 Jun 11;11:76. doi: 10.1186/1465-9921-11-76.

28.

Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells.

Lane N, Robins RA, Corne J, Fairclough L.

Clin Sci (Lond). 2010 Apr 20;119(2):75-86. doi: 10.1042/CS20100033. Review.

PMID:
20402669
29.

Quantitative validation and comparison of multiplex cytokine kits.

Richens JL, Urbanowicz RA, Metcalf R, Corne J, O'Shea P, Fairclough L.

J Biomol Screen. 2010 Jun;15(5):562-8. doi: 10.1177/1087057110362099. Epub 2010 Feb 22.

PMID:
20176857
30.

Altered effector function of peripheral cytotoxic cells in COPD.

Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC.

Respir Res. 2009 Jun 22;10:53. doi: 10.1186/1465-9921-10-53.

31.

Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.

Richens JL, Urbanowicz RA, Lunt EA, Metcalf R, Corne J, Fairclough L, O'Shea P.

Respir Res. 2009 Apr 22;10:29. doi: 10.1186/1465-9921-10-29. Review.

32.

Allergen-driven suppression of thiol production by human dendritic cells and the effect of thiols on T cell function.

Hasan AA, Ghaemmaghami AM, Fairclough L, Robins A, Sewell HF, Shakib F.

Immunobiology. 2009;214(1):2-16. doi: 10.1016/j.imbio.2008.04.006. Epub 2008 Jun 20.

PMID:
19159822
33.

Killer cells in chronic obstructive pulmonary disease.

Fairclough L, Urbanowicz RA, Corne J, Lamb JR.

Clin Sci (Lond). 2008 Apr;114(8):533-41. doi: 10.1042/CS20070356. Review.

PMID:
18336369
34.

Xenopus laevis transgenesis by sperm nuclear injection.

Smith SJ, Fairclough L, Latinkic BV, Sparrow DB, Mohun TJ.

Nat Protoc. 2006;1(5):2195-203.

PMID:
17406457
35.

The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on peripheral blood B cells, dendritic cells and monocyte subsets.

Richens J, Fairclough L, Ghaemmaghami AM, Mahdavi J, Shakib F, Sewell HF.

Immunobiology. 2007;212(1):29-38. Epub 2006 Sep 18.

PMID:
17270707
36.

The metrics of clinical trials.

Wright J, Fairclough L, Manzo J, Phippard L, Smuck B, Lacourciere J.

J Clin Oncol. 2005 Mar 1;23(7):1589-90; author reply 1590-1. No abstract available.

PMID:
15735144
37.

Regulation of apoptosis in theXenopus embryo by Bix3.

Trindade M, Messenger N, Papin C, Grimmer D, Fairclough L, Tada M, Smith JC.

Development. 2003 Oct;130(19):4611-22.

38.

Determinants of T box protein specificity.

Conlon FL, Fairclough L, Price BM, Casey ES, Smith JC.

Development. 2001 Oct;128(19):3749-58.

39.

Phantom dosimetry for conformal stereotactic radiotherapy with a head and neck localizer frame.

Ravindra BP, Fairclough L, Jaywant SM.

Phys Med Biol. 2001 Jul;46(7):1975-84.

PMID:
11474938
40.

Bix4 is activated directly by VegT and mediates endoderm formation in Xenopus development.

Casey ES, Tada M, Fairclough L, Wylie CC, Heasman J, Smith JC.

Development. 1999 Oct;126(19):4193-200.

41.

Bix1, a direct target of Xenopus T-box genes, causes formation of ventral mesoderm and endoderm.

Tada M, Casey ES, Fairclough L, Smith JC.

Development. 1998 Oct;125(20):3997-4006.

43.

Poor reward. Interview by Phil Cohen.

Fairclough L.

Nurs Times. 1995 Jan 11-17;91(2):17. No abstract available.

PMID:
7838760
44.

Analysis of structure and expression of the Xenopus thyroid hormone receptor-beta gene to explain its autoinduction.

Machuca I, Esslemont G, Fairclough L, Tata JR.

Mol Endocrinol. 1995 Jan;9(1):96-107.

PMID:
7760854
45.
46.

A new qualitative variant of the RhE antigen revealed by heterogeneity among anti-E sera.

Lubenko A, Burslem SJ, Fairclough LM, Pope J, Boyd D, Bacon J.

Vox Sang. 1991;60(4):235-40.

PMID:
1718091

Supplemental Content

Loading ...
Support Center